Immunotherapeutic Strategies in Breast Cancer:Preclinical and Clinical Trials
Abstract
This project is focused on novel tumor vaccines directed at MUC1 and other tumor antigens. Our specific aims are: 1)To assess the effectiveness of vaccines against MUC1 and other tumor antigens in the prevention and treatment of spontaneous breast carcinomas in mice; 2)To translate an effective vaccine strategy into a phase I clinical trial in patients with undetectable disease following standard therapy. We have tested five vaccines in the preclinical mouse models and all elicited a strong immune response. The vaccine using MUC1 class I binding peptides prevented MUC1-expressing tumor growth. We have designed the Phase I clinical trial using a peptide vaccine comprised of MUC1 and HER-2/neu MHC class I peptides and HER-2/neu MHC class II peptide with unmethylated CpG oligodeoxynucleotides and GM-CSF as adjuvants in breast cancer patients free of disease. Thirty-nine patients were enrolled. There was significant adjuvant-dependent sensitization to MUC1; a similar trend was observed for HER-2/neu. The combination vaccine of MUC1 and HER-2/neu peptides resulted in a high-frequency of immune responses with transient injection site reactions. Further studies for breast cancer are warranted.
Document Details
- Document Type
- Technical Report
- Publication Date
- Sep 01, 2012
- Accession Number
- ADA582548
Entities
People
- Sandra J. Gendler
Organizations
- Mayo Clinic Scottsdale